Showing results (91-100 of 126) with videos related to

Sort By:
Pageof 13
Cancer Research|December 5, 2024
Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in MelanomaCatriona A Ford, Dana Koludrovic, Patricia P Centeno, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|April 16, 2011
Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathiesKatherine A Rauen, Anuradha Banerjee, W Robert Bishop, et al.
Cell Reports|November 14, 2015
AKT1 Activation Promotes Development of Melanoma MetastasesJoseph H Cho, James P Robinson, Rowan A Arave, et al.
Human Molecular Genetics|September 24, 2013
Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formationAlice F Goodwin, William E Tidyman, Andrew H Jheon, et al.
Oncogene|April 30, 2003
Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cellsJohn G Shelton, Linda S Steelman, John T Lee, et al.
Genes & Development|May 3, 2012
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesisLiesbeth C W Vredeveld, Patricia A Possik, Marjon A Smit, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2012
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapyEmmanuelle Huillard, Rintaro Hashizume, Joanna J Phillips, et al.
Oncotarget|October 8, 2016
Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma modelStefan Grossauer, Katharina Koeck, Nicole E Murphy, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Characterization of the BRAF interactome identifies BRAF V600E TP53 interaction in melanomaKayla T O'Toole, Adamaris Martinez, Brandon Murphy, et al.
Elife|August 30, 2024
Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancerPhaedra C Ghazi, Kayla T O'Toole, Sanjana Srinivas Boggaram, et al.
Pageof 13